Bionic nanoparticles for photothermal and photodynamic combined treatment of tuberculosis as well as preparation method and application of bionic nanoparticles

By designing nanoparticles coated with red blood cell membranes, the perfluorocarbon compounds and AIE photosensitizers are loaded with blood circulation to enhance the effects of photothermal and photodynamic therapy, the combined problem of photothermal and photodynamic therapy in the prior art is solved, and the combination of photothermal and photodynamic therapy has been achieved. Effective targeting and long-term treatment of tuberculosis granuloma reduce the risk of drug resistance.

CN119033930APending Publication Date: 2024-11-29KUNMING MEDICAL UNIVERSITY +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410957118.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-17
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing photothermal and photodynamic treatment plans cannot be used effectively, and lasting phototherapy cannot be achieved at the site of tuberculosis granuloma, and there are drug resistance and side effects.

Method used

Using the outer membrane-coated bionic nanoparticle structure, the Prussian blue nanoparticles loaded with perfluorocarbons and AIE-type photosensitizer PEG250-TQ are used to enhance permeability and retention effects through blood circulation and release under laser irradiation. Oxygen and light energy realize combined treatment of photothermal and photodynamics.

Benefits of technology

Improve the effectiveness and safety of photodynamic therapy, enhance the killing ability of Mycobacterium tuberculosis, reduce the damage to normal tissues by high temperature, and provide a new treatment plan with good biosafety and significant Suppression effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033930A_ABST
    Figure CN119033930A_ABST
Patent Text Reader

Abstract

The invention discloses a bionic nano particle for photothermal and photodynamic combined treatment of tuberculosis as well as a preparation method and application of the bionic nano particle. The bionic nano particle is of a structure that an outer membrane wraps a core, the outer membrane is an erythrocyte membrane, and the core is a Prussian blue nano particle RBC-O2 / TQ-coated PB loaded with a perfluorocarbon compound, oxygen and an aggregation-induced emission type photosensitizer PEG250-TQ. The bionic nanoparticle RBC-O2 / TQ-coated PB provided by the invention has a selective accumulation effect on granuloma tuberculosis, can be circulated in the body for a long time, and shows an obvious photo-thermal and photodynamic combined effect of killing mycobacterium tuberculosis under laser irradiation, thereby opening up a new way for the treatment of tuberculosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of tuberculosis treatment, and specifically relates to a bionic nanoparticle for combined photothermal and photodynamic treatment of tuberculosis, and a preparation method and application thereof. Background Art

[0002] Tuberculosis is a highly contagious and fatal disease caused by the pathogenic bacterium Mycobacterium tuberculosis. According to the World Health Organization, latent Mycobacterium tuberculosis infection affects about a quarter of the world's population, with 7.5 million new cases and 1.3 million deaths in 2022. The anti-tuberculosis drugs currently used in clinical practice are mainly antibiotics. However, antibiotic treatment has some limitations, such as drug resistance, short drug half-life, and significant side effects. Therefore, there is an urgent need to develop new drugs that can overcome these limitations and have good biocompatibility.

[0003] Phototherapy, including photodynamic therapy (PDT) and photothermal therapy (PTT), is a promising alternative to conventional antibiotic therapy due to its non-invasiveness and effective killing of bacteria, and neither PDT nor PTT has been shown to induce bacterial resistance. During PDT treatment, photosensitizers and oxygen generate reactive oxygen species with oxidative damage under laser irradiation. Of particular interest are aggregation-induced emission (AIE) characteristic photosensitizers, which show broad application in imaging-guided PDT due to their superior fluorescence emission and increased generation of reactive oxygen species in the aggregated state compared to traditional photosensitizers. In addition to photosensitizers, the efficacy of PDT also depends on the oxygen level within the granuloma, which is a characteristic structure of tuberculosis. Hypoxia in the granuloma hinders the generation of reactive oxygen species in PDT, and existing PDT nanoparticles have poor permeability and retention effects, and cannot be effectively enriched at the site of tuberculosis granulomas, resulting in the inability to achieve long-lasting phototherapy.

[0004] At present, patent CN 118141782 A discloses a bionic nanoparticle for tuberculosis diagnosis and photothermal therapy, and its preparation method and application, wherein the bionic nanoparticle is a structure of an outer membrane covering a core, the outer membrane is a cell membrane of a macrophage pre-activated by Mycobacterium marinum, and the core is an aggregation-induced luminescence composite material with aggregation-induced heating characteristics. The bionic nanoparticles provided by the invention can achieve dual targeting of tuberculosis granulomas and pathogens in granulomas, but it can only achieve photothermal therapy for pulmonary tuberculosis, but cannot achieve photodynamic therapy. At present, the combined treatment of PDT and PTT for tumors has become increasingly mature, and there are few treatment plans for the combined treatment of tuberculosis with PDT and PTT. Summary of the invention

[0005] The purpose of the present invention is to overcome the above-mentioned defects and deficiencies in the prior art and to provide a bionic nanoparticle for combined photothermal and photodynamic therapy of tuberculosis.

[0006] The second object of the present invention is to provide a method for preparing bionic nanoparticles for combined photothermal and photodynamic therapy of tuberculosis.

[0007] The third object of the present invention is to provide a method for preparing a drug preparation for treating tuberculosis, comprising using bionic nanoparticles for combined photothermal and photodynamic therapy for tuberculosis.

[0008] The fourth object of the present invention is to provide a pharmaceutical preparation containing bionic nanoparticles for combined photothermal and photodynamic therapy of tuberculosis.

[0009] The above-mentioned object of the present invention is achieved through the following technical solutions: The present invention provides a bionic nanoparticle for combined photothermal and photodynamic therapy of tuberculosis. The bionic nanoparticle is a structure in which an outer membrane covers a core, the outer membrane is a red blood cell membrane (RBC), and the core is loaded with perfluorocarbon compound (PFC), oxygen and AIE type photosensitizer PEG. 250 -TQ Prussian blue (PB) nanoparticles. That is, by loading PFC and AIE photosensitizer (PEG 250 -TQ) Construction of biomimetic red blood cell membrane functionalized PB nanoparticles RBC-O 2 / TQ@PB; the AIE type photosensitizer PEG 250 The structural formula of -TQ is as follows: .

[0010] Perfluorocarbons (PFCs) have been approved by the U.S. Food and Drug Administration as bionic blood capable of delivering oxygen due to their high oxygen-carrying capacity, excellent biocompatibility, and bioinertness. By providing oxygen to hypoxic granulomas, the production of reactive oxygen species used to kill Mycobacterium tuberculosis is increased. The present invention is beneficial to improving the efficacy of PDT by adopting novel AIE photosensitizers and PFC-mediated oxygen delivery. Prussian blue (PB) nanoparticles have been widely developed as photothermal ablative agents and nanocarriers loaded with photosensitizers in PDT applications. These PB nanoparticles can exert long-lasting phototherapy through long blood circulation. The red blood cell membrane (RBC) is a natural long-cycle transport carrier, which inspires the design of artificial biomaterials and delivery systems.

[0011] The present invention uses Prussian blue PB as both a carrier and a drug for photothermal effect, utilizes oxygen self-supply enhanced photodynamic therapy, and through the modification of red blood cell membrane, realizes long-term cycle enhanced photothermal and photodynamic combined treatment of tuberculosis. Specific process: The high-efficiency and low-toxic nano drug RBC-O prepared by the present invention 2After entering the blood circulation, the red blood cell membrane endows the nanodrug with a long blood circulation property, which promotes the enrichment of the nanodrug in the tuberculosis granuloma through enhanced permeability and retention effect. After reaching the tuberculosis granuloma, the hypoxic environment of the granuloma induces the nanodrug to release oxygen. Under laser irradiation, the increase in oxygen enhances the RBC-O 2 AIE-type photosensitizer PEG in / TQ@PB 250 -TQ has the ability to produce singlet oxygen, thereby amplifying the photodynamic killing effect of Mycobacterium tuberculosis; on the other hand, under laser irradiation, the nanodrug RBC-O 2 / TQ@PB can convert the absorbed light energy into heat, exerting photothermal killing effect on Mycobacterium tuberculosis. The combined treatment of PDT and PTT of the present invention provides a new treatment option for tuberculosis. PTT involves converting light energy into heat energy, causing irreversible thermal ablation of target bacteria without the risk of induced drug resistance. The local heat generated by PTT may increase the blood flow of tuberculosis granulomas, help oxygen replenishment and support bacterial elimination. In addition, the reactive oxygen species generated during PDT can reduce the expression of heat shock proteins, weaken the heat resistance of bacteria to PTT, reduce the damage of high temperature to normal tissues around the granuloma, and ultimately improve the effectiveness and safety of PTT treatment.

[0012] Furthermore, the above-mentioned perfluorocarbon compound is perfluorotributylamine.

[0013] The present invention provides a method for preparing bionic nanoparticles for combined photothermal and photodynamic therapy of tuberculosis, comprising the following steps: S1. Preparation of PFC@PB: PFC@PB was prepared by injecting perfluorocarbon compound PFC into the mesoporous cavity of Prussian blue PB nanoparticles; S2.O 2 Preparation of PFC@PB: PFC@PB was oxygenated to obtain O 2 @PB; S3.O 2 Preparation of / TQ@PB: AIE photosensitizer PEG 250 -TQ loaded to O 2 @PB, prepared O 2 / TQ@PB; S4. RBC-O 2 Preparation of TQ@PB: Red blood cell membrane and O 2 / TQ@PB solution was mixed and co-extruded to prepare RBC-O 2 / TQ@PB bionic nanoparticles.

[0014] Furthermore, the preparation method of Prussian blue PB nanoparticles in step S1 is to 3[Fe(CN) 6 ], PVP and HCl are mixed in deionized water, treated by ultrasound and centrifuged to obtain.

[0015] Furthermore, in the above step S1, the perfluorocarbon compound PFC is injected into the mesoporous cavity of the Prussian blue PB nanoparticles to prepare PFC@PB by ultrasonically mixing the perfluorocarbon PFC and the Prussian blue PB nanoparticles in ice water.

[0016] Furthermore, in the above step S1, the mass volume ratio of Prussian blue PB nanoparticles to perfluorocarbon PFC is 1 mg Prussian blue: 5-20 μL perfluorocarbon.

[0017] Furthermore, the oxygenation condition described in step S2 is an oxygenation flow rate of 2 to 8 L min -1 , oxygenation time is 5~15min.

[0018] Preferably, the oxygenation condition in step S2 is an oxygenation flow rate of 5 L min -1 , oxygenation time 10 min.

[0019] Furthermore, the oxygenation in step S2 is to place the PFC@PB sample tube in a sterile oxygen chamber to oxygenate the prepared O 2 @PB.

[0020] Furthermore, in step S3, the AIE photosensitizer PEG 250 -TQ loaded to O 2 @PB is the AIE type photosensitizer PEG 250 - After TQ is dissolved, it reacts with O 2 @PB was mixed and stirred at room temperature for 22 to 26 h to prepare O 2 / TQ@PB.

[0021] Furthermore, the AIE type photosensitizer PEG 250 -TQ is dissolved in an organic solvent.

[0022] Preferably, the organic solvent is dimethyl sulfoxide.

[0023] Furthermore, the AIE type photosensitizer PEG in step S3 above 250 -TQ and O 2 @The mass ratio of PB is 1:1~3.

[0024] Furthermore, the method for collecting red blood cell membranes described in the above step S4 is to take whole blood and centrifuge it at 4°C, and keep the red precipitate at the lower layer. Wash the precipitate with PBS. Then, resuspend the precipitate with ultrapure water and place it at 4°C to absorb water and swell for 1 hour. Then centrifuge it at 12000g for 5 minutes, and wash it with water until the supernatant is colorless. Next, use a cell ultrasonic disruptor to ultrasonically treat the collected red blood cell membranes for 5 minutes.

[0025] Furthermore, the coextrusion in step S4 is to combine the red blood cell membrane RBC with O 2 -TQ@PB nanoparticle blends passed through filter membranes with pore sizes of 400 nm and 200 nm in sequence.

[0026] The present invention utilizes the prepared high-efficiency and low-toxic nanoparticle RBC-O 2 / TQ@PB, targeted to the granuloma site through enhanced permeability and retention, benefiting from increased circulation time in the blood, RBC-O 2 / TQ@PB nanoparticles can increase the accumulation of granulomas and ensure long-lasting phototherapy. 2 / TQ@PB nanoparticles deliver oxygen to help alleviate the hypoxic microenvironment in granulomas, increase the production of reactive oxygen species and enhance the elimination of Mycobacterium tuberculosis. At the same time, PB nanoparticles convert light into heat, causing thermal damage to the bacteria. The combination of PTT and PDT based on hypoxia relief enhancement and biomimetic red blood cell membrane provides a new paradigm for long-term phototherapy for tuberculosis. Therefore, nanomedicine RBC-O 2 / TQ@PB has good biosafety and significant inhibition of the growth of Mycobacterium tuberculosis in the treatment of pulmonary tuberculosis, and has the advantages of high efficiency and low toxicity of nanomedicine, and plays the advantages of light treatment for tuberculosis.

[0027] Therefore, the present invention also provides the use of any of the above-mentioned bionic nanoparticles in the preparation of a drug preparation for the treatment of tuberculosis.

[0028] The present invention provides a pharmaceutical preparation comprising any of the above-mentioned bionic nanoparticles for combined photothermal and photodynamic therapy of tuberculosis.

[0029] Furthermore, the above-mentioned kit also includes pharmaceutically acceptable excipients.

[0030] Compared with the prior art, the present invention has the following beneficial effects: The bionic nanoparticle RBC-O of the present invention 2 / TQ@PB can be used for long-term circulation-enhanced tuberculosis granuloma-targeted photothermal and photodynamic therapy for tuberculosis. RBC-O 2 / TQ@PB in the blood circulation, due to the modification of the red blood cell membrane, its blood circulation time is increased and the enrichment of tuberculosis granuloma is increased. 2 / TQ@PB helps to alleviate the hypoxic microenvironment in granulomas, increase the production of reactive oxygen species and enhance the elimination of Mycobacterium tuberculosis. Under laser irradiation, it can play an efficient photothermal and photodynamic combined treatment for Mycobacterium tuberculosis. The RBC-O prepared by the present invention 2 / TQ@PB nanomedicine has a significant therapeutic effect on tuberculosis model mice, opening up a new path for granuloma-targeted enhanced photothermal and photodynamic combined treatment of tuberculosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 PEG 250 -OTs 1 H NMR spectrum.

[0032] Figure 2 PEG 250 -OTs 13 C NMR spectrum.

[0033] Figure 3 PEG 250 -TPA-Br 1 H NMR spectrum.

[0034] Figure 4 PEG 250 -TPA-Br 13 C NMR spectrum.

[0035] Figure 5 PEG 250 -TPA-NO 2 of 1 H NMR spectrum.

[0036] Figure 6 PEG 250 -TPA-NO 2 of 13 C NMR spectrum.

[0037] Figure 7 PEG 250 -TQ 1 H NMR spectrum.

[0038] Figure 8 PEG 250 -TQ 13 C NMR spectrum.

[0039] Fig. 9 PEG 250 -High-resolution mass spectra of TQ.

[0040] Fig.10 PEG 250 -PL spectrum of TQ. Fig.10 (a) is the ratio of THF / water to water. f W PEG 250 -PL spectra of TQ; (b) PEG in different THF / Water mixing volume ratios 250 -Relative emission intensity of TQ compounds. I 0 and I PEG 250 -Peak intensity of photoluminescence of TQ in THF and THF / water mixtures.

[0041] Fig.11 PEG 250 - Molecular orbital amplitude diagram of the highest occupied molecular orbital (HOMO) and lowest unoccupied molecular orbital (LUMO) energy levels of TQ. Energy gap = LUMO-HOMO.

[0042] Fig.12 PEG 250 -TQ characterization. Among them, Fig.12 (a) PEG 250 -Chemical structure of TQ; (b) PEG 250 PL spectrum of -TQ in THF; (c) laser irradiation of PEG in the presence of SOSG 250 -PL spectrum of SOSG after TQ.

[0043] Fig.13 RBC-O 2 / Schematic diagram of the working principle of TQ@PB nanomedicine.

[0044] Fig.14 RBC-O 2 Transmission electron microscopy (a) and particle size image (b) of / TQ@PB nanomedicine.

[0045] Fig.15 RBC membrane and RBC-O 2 Gel electrophoresis of Coomassie blue-stained proteins of / TQ@PB nanoparticles.

[0046] Fig.16 PB nanoparticles, PEG 250 -TQ nanoparticles, red blood cell membranes and RBC-O 2 UV-visible absorption graph of / TQ@PB nanomedicine.

[0047] Fig.17Different concentrations of RBC-O 2 Temperature change curve of / TQ@PB solution under light.

[0048] Fig.18 RBC-O 2 / Detection diagram of oxygen carried by TQ@PB.

[0049] Fig.19 This is a graph showing the fluorescence intensity of singlet oxygen in solution.

[0050] Fig. 20 Images of colony plates after incubation of BCG with different nanodrugs with and without laser irradiation.

[0051] Fig.21 Nanodrugs O were injected intravenously into rats. 2 / TQ@PB、RBC-O 2 Relative signals of nanomedicine in plasma after / TQ@PB.

[0052] Fig. 22 RBC-O 2 / Distribution of TQ@PB nanodrugs in the main organs of tuberculosis mice.

[0053] Fig.23 H&E staining of the lungs of mice with tuberculosis after in vivo treatment.

[0054] Fig.24 Nanomedicine RBC-O 2 / Hemolytic test of TQ@PB. DETAILED DESCRIPTION

[0055] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0056] Unless otherwise specified, the reagents and materials used in the following examples are commercially available.

[0057] The attenuated strain of bovine tuberculosis (bacillus Calmette-Guerin, BCG) is related to Mycobacterium tuberculosis and is an excellent model for studying Mycobacterium tuberculosis. In this manual, experiments were conducted using BCG, and the conclusions of each experiment are applicable to tuberculosis.

[0058] Example 1 AIE-type photosensitizer PEG 250 Synthesis of -TQ

[0059] PEG 250-Specific steps of TQ synthesis:

[0060] PEG 250 Synthesis of -OTs: Triethylamine (15.8 mL, 119 mmol) was added to a solution of pentaethylene glycol monomethyl ether (2,5,8,11,14-pentaoxheexadecan-16-ol) (10 g, 39.7 mmol) in anhydrous DCM (50 mL) under ice bath conditions. The resulting mixture was stirred for 2 h, and 4-formyl chloride (22.8 g, 119 mmol) was added. The resulting mixture was stirred for 18 h, quenched with water, and then quenched with CH 2 Cl 2 The combined organic layers were washed with anhydrous Na 2 SO 4 After the solvent was removed, the crude product was obtained, which was purified by silica gel column chromatography (DCM:MeOH=50:1) to obtain a colorless transparent oil (14 g, yield 88%). 1 H NMR (400 MHz, THF- d 8 ) δ 7.67 (d, J = 8.1 Hz, 2H), 7.29 (d, J = 8.0 Hz,2H), 3.99 (dd, J = 6.9, 2.4 Hz, 2H), 3.46–3.38 (m, 16H), 3.16 (s, 3H), 2.31 (s, 3H). 13 C NMR (101 MHz, THF- d 8 ) δ 144.58, 133.85, 129.74, 127.85, 71.94, 70.52,70.49, 70.46, 70.36, 69.50, 69.44, 68.55.

[0061]

[0062] PEG 250 Synthesis of -TPA-Br: In a 50 mL two-necked round-bottom flask, a mixture of HO-TPA-Br (0.1775 g, 1 mmol) and MeCN (20 mL) was added. 250 -OTs (1.218 g, 3 mmol) and K 2 CO 3(0.2070 g, 1.5 mmol). The mixture was heated to 85 °C and stirred overnight. After the reaction was completed, the solvent was removed by rotary evaporation and purified by chromatography (DCM: MeOH = 40: 1) to obtain a colorless, transparent oily liquid product (0.691 g, 94%). 1 H NMR (400 MHz, THF- d 8 )δ 7.11 (d, J = 8.9 Hz, 2H), 6.91–6.87 (m, 4H), 6.78–6.74 (m, 4H), 6.65 (d, J =6.8 Hz, 2H), 3.97–3.93 (m, 4H), 3.67 (dd, J = 5.7, 4.2 Hz, 4H), 3.43 (s, 40H), 3.34-3.31 (m, 4H), 3.16 (s, 6H). 13 C NMR (101 MHz, THF- d 8 ) δ 155.83, 148.27,140.43, 131.58, 126.55, 121.62, 115.41, 111.75, 71.96, 70.73, 70.63, 70.61,70.57, 70.41, 69.62, 58.06.

[0063]

[0064] PEG 250 -TPA-SnBu 3 Synthesis route: Under nitrogen conditions at -78°C, add n-butyllithium (n-BuLi: 0.8mL, 2.5 M, 2 mmol) to PEG 250 -TPA-Br (0.7352 g, 1 mmol) in anhydrous THF (12 mL). Tributyltin chloride (0.5 mL, 1 mmol) was injected 2 h later. The resulting mixture was stirred overnight, quenched with water, extracted three times with EA, and washed with water in anhydrous Na 2 SO 4 After the solvent was removed, a crude product was obtained.

[0065]

[0066] PEG 250 -TPA-NO 2The synthetic route is: Pd(PPh 3 ) 4 (0.0145 g, 0.0125 mmol) and 4,7-dibromo-5,6-dinitrobenzene[c][1,2,5]thiadiazole (0.144 mg, 0.375 mmol). The mixture was heated to reflux and stirred overnight. The solvent was then removed and the crude product was purified by column chromatography (DCM:MeOH=30:1) to obtain PEG 250 -TPA-NO 2 , a purple oily liquid (0.3147 g, 49%). 1 H NMR (600 MHz, Chloroform- d ) δ7.35 (d, J = 12.1 Hz, 4H), 7.14 (s, 8H), 6.95 (d, J = 16.3 Hz, 4H), 6.89 (d, J =3.5 Hz, 8H), 4.13 (t, J = 4.8 Hz, 8H), 3.87 (d, J = 4.8 Hz, 8H), 3.73 (s, 8H), 3.66 (s, 56H), 3.55 (d, J = 2.0 Hz, 8H), 3.37 (s, 12H). 13 C NMR (151 MHz, Chloroform- d ) δ 156.05, 139.61, 130.15, 127.82, 127.53, 117.94, 115.68,115.59, 72.67, 71.93, 71.89, 70.84, 70.61, 70.58, 69.73, 67.69.

[0067]

[0068] PEG 250 -TQ synthesis route: PEG 250 -TPA-NO 2 (0.21 g, 0.12 mmol) and acetic acid (5 mL) were mixed in a 50 mL two-necked round-bottom flask, and iron powder (0.0211 g, 0.3 mmol) was added. The mixture was heated to 80 °C, stirred for 4 h, cooled to room temperature, added with water, and washed three times with dichloromethane. The organic phase was washed with Na 2 SO 4The crude product and benzil (0.0588 g, 0.24 mmol) were dissolved in a mixture of acetic acid (2 mL) and chloroform (2 mL) in a 15 mL tube and heated under N 2 The mixture was then heated to 80°C, stirred for 12 h, cooled to room temperature, added with water, and extracted three times with dichloromethane. The organic phases were combined and 2 SO 4 After drying, the solvent was evaporated under reduced pressure. The product was separated by silica gel column chromatography (DCM: MeOH = 25: 1) to obtain PEG 250 -TQ purple, dark green solid (0.164 g, 75%). 1 H NMR (400 MHz, THF- d 8 ) δ 7.83 (d, J = 6.8 Hz, 4H), 7.56 (d, J = 8.0 Hz, 4H), 7.25–7.18 (m, 6H), 7.07 (d, J = 6.7 Hz, 8H), 6.99–6.95 (m, 4H), 6.84–6.80 (m, 8H), 3.99 (dd, J = 5.8, 4.2 Hz, 8H), 3.70 (dd, J = 5.7, 4.3 Hz, 8H), 3.50–3.42 (m, 56H), 3.33–3.30 (m, 8H), 3.15 (s, 12H) 13 C NMR (101 MHz, THF- d 8 ) δ 156.35,153.76, 152.84, 149.27, 141.23, 139.54, 136.34, 134.50, 130.45, 129.50,128.90, 128.33, 127.43, 127.39, 118.71, 115.78, 72.45, 71.24, 71.14, 71.11,71.07, 70.91, 70.16. HRMS (ESI) calculated for C 100 H 126 N 6 O 40 S [M+H] + : 1827.8617;Found: 1828.8621.

[0069] In this example, a new organic photosensitizer (PEG 250 -TQ)( Fig.12 a). Through 1 H and 13 C NMR ( Figure 1-8 ) and high-resolution mass spectrometry ( Fig. 9 ) verified that PEG 250 -Chemical structure of TQ. PEG 250 -TQ has an absorption peak of about 660 nm in tetrahydrofuran (THF), and its 900 nm photoluminescence band is in the range of 750 to 1200 nm and has a large proportion in the second near-infrared (NIR-II) window (>1000 nm) ( Fig.12 b). In addition, PEG 250 -TQ has typical AIE properties, with weak emission in dilute solution and significantly enhanced fluorescence when aggregated or in the solid state due to the restriction of intramolecular motion ( Fig.10 ). Then, PEG is calculated 250 The highest occupied molecular orbital and the lowest unoccupied molecular orbital of -TQ are -4.45 eV and -2.75 eV, respectively, and its band gap is 1.70 eV ( Fig.11 As a new type of photosensitizer, PEG 250 -TQ's ROS-generating capacity was determined using the fluorescent probe Singlet Oxygen Sensor Green (SOSG), which emits strong fluorescence. 250 After irradiation of the -TQ aqueous solution, the emission intensity of SOSG gradually increased ( Fig.12 c), indicating that PEG 250 -TQ is a potential AIE-type photosensitizer.

[0070] Example 2 RBC-O 2 Synthesis and characterization of / TQ@PB nanomedicine Bionic nanomedicine RBC-O 2 The preparation steps of / TQ@PB are as follows: S1. Preparation of Prussian blue PB nanoparticles: The preparation of PB nanoparticles was adjusted according to the patent (Patent No.: ZL202210532390.1, Invention Name: A tumor nanomedicine based on polyethyleneimine and Prussian blue and its preparation method and application). 0.825 g K 3 [Fe(CN) 6], 18 g PVP and 202.5 μL HCl (mass fraction of 36% to 38%) were mixed in 150 mL deionized water and a clear solution was obtained after ultrasonication at room temperature; next, the reaction was carried out at 80 °C for 20 h; PB was collected after centrifugation at 21380 g for 15 min and then washed in deionized water to prepare Prussian blue PB nanoparticles.

[0071] S2.O 2 Preparation of / TQ@PB: 80 µL of perfluorotributylamine (a type of PFC) and 8 mg of PB were mixed in ice water and sonicated for 8 minutes, and 10 mL of PBS solution was added to cover the PFC in the PB (labeled as PFC@PB). To achieve oxygen saturation, the PFC@PB sample tube was placed in a sterile oxygen chamber for 10 min (O 2 Flow rate: 5 L min -1 ), and get O 2 @PB.

[0072] S3. AIE-type photosensitizer PEG 250 -TQ loading, PEG 250 -TQ (1 mg mL -1 , 2 mL) was dissolved in DMSO and mixed with O 2 @PB (2 mg mL -1 , 2 mL) and stirred at room temperature for 24 h. Free PEG was removed by centrifugation using an ultrafiltration centrifuge tube (molecular weight cutoff 30 kDa). 250 -TQ gets O 2 / TQ@PB; S4. RBC-O 2 Preparation of / TQ@PB: Take whole blood from C57BL / 6 mice, centrifuge at 300 g for 5 min at 4°C, and keep the red precipitate at the bottom. Wash the precipitate with PBS and centrifuge at 300 g for 5 min until the supernatant is colorless. Then resuspend the red blood cell precipitate in ultrapure water and place it at 4°C to absorb water and swell for 1 hour. Then centrifuge the red blood cell membrane at 12000g for 5 minutes and wash it with water until the supernatant is colorless. Next, use a cell ultrasonic disruptor to sonicate the collected RBC membrane for 5 minutes. Mix the RBC membrane with 500μL O 2 / TQ@PB solution (0.2 mg mL -1 ) were mixed and passed through membranes with pore sizes of 400 nm and 200 nm in sequence to prepare RBC-O 2 / TQ@PB.

[0073] Biomimetic nanomedicine RBC-O based on combined photothermal and photodynamic therapy for tuberculosis granuloma targeting 2 / TQ@PB's principles of tuberculosis pathogen targeting, diagnostic imaging, and photothermal combined with oxygen supply enhanced photodynamic therapy Fig.13 As shown. 2 / TQ@PB is characterized as follows: (1) RBC-O 2 Morphology, hydrated particle size distribution and hydrodynamic size of / TQ@PB nanomedicine like Fig.14 As shown in a, transmission electron microscopy shows PB and RBC-O 2 / TQ@PB are all cubic structures with a particle size of about 100nm. 2 / TQ@PB membrane thickness is about 7 nm, proving that the red blood cell membrane is successfully coated. Fig.14 b, dynamic light scattering determination of PB and RBC-O 2 / The hydrodynamic size of TQ@PB. After PB was modified with red blood cell membrane, the particle size increased, which indirectly indicated that the red blood cell membrane was successfully modified onto the PB surface.

[0074] (2) Verification of biomimetic nanomedicine RBC-O by gel electrophoresis 2 Protein abundance on TQ@PB like Fig.15 As shown, by comparing RBC membrane proteins with RBC-O 2 / TQ@PB membrane protein expression, found RBC-O 2 / TQ@PB membrane protein expression band is consistent with that of RBC membrane protein, indicating that RBC-O 2 / TQ@PB inherits the characteristic proteins of RBC membrane, which is conducive to the long circulation of this bionic nanomedicine in vivo.

[0075] (3) Bionic nanomedicine RBC-O 2 / TQ@PB absorption spectrum characterization like Fig.16 As shown, by comparing RBC membrane, PB and PEG 250 -TQ characteristic absorption peak shows that the bionic nanomedicine RBC-O 2 The UV-visible absorption spectrum of / TQ@PB shows a typical absorption peak of RBC membrane at 400 nm, and PB or PEG 250 -TQ has an absorption peak at about 700 nm, which indicates that RBC-O 2 / Successful preparation of TQ@PB.

[0076] (4) Bionic nanomedicine RBC-O 2 / TQ@PB Photothermal Properties Verification PB has near-infrared absorption and can convert the absorbed light energy into heat energy under laser irradiation, thus exerting the effect of photothermal therapy.

[0077] like Fig.17 As shown, under laser irradiation, RBC-O 2 / TQ@PB solution temperature increases with increasing concentration. 2 When the concentration of / TQ@PB solution was 400 μg mL-1, its temperature increased by 31.7℃ within 5 min, showing excellent photothermal performance.

[0078] (5) Bionic nanomedicine RBC-O 2 / Verification of oxygen carrying capacity of TQ@PB Granuloma is a characteristic structure of tuberculosis, and its hypoxic characteristics severely limit the effectiveness of PDT. Delivering oxygen to granulomas can help increase the production of reactive oxygen species during PDT, thereby improving the efficacy of PDT in the treatment of tuberculosis. 3 ]Cl 2 Determination of RBC-O 2 / TQ@PB's O 2 Delivery capacity. [Ru(dpp) 3 ]Cl 2 The fluorescence is quenched under oxygen-rich conditions.

[0079] like Fig.18 As shown, compared with PBS and RBC-TQ@PB, RBC-O 2 / TQ@PB group [Ru(dpp) 3 ]Cl 2 The fluorescence intensity is the lowest, indicating that RBC-O 2 / TQ@PB has the highest oxygen content, proving that RBC-O 2 / TQ@PB successfully carried oxygen.

[0080] (6) Biomimetic nanomedicine RBC-O 2 Detection of the ability of TQ@PB to produce singlet oxygen To kill M. tuberculosis, PDT uses photosensitizers to convert oxygen from triplet state to singlet state, which is cytotoxic. 1 O 2 , a type of reactive oxygen species). The singlet oxygen-specific fluorescent probe SOSG was used to analyze RBC-O 2 / TQ@PB 1 O 2 Production level, SOSG encountered 1 O 2 After fluorescence enhancement.

[0081] like Fig.19 As shown in the figure, after laser irradiation, the fluorescence intensity of SOSG gradually increased with the extension of laser irradiation time. 2 / TQ@PB provides additional oxygen, RBC-O 2 / TQ@PB 1 O 2 The yield was significantly higher than that of PBS and RBC-TQ@PB. 2 / TQ@PB can improve granuloma hypoxia through self-oxygen supply and enhance 1 O 2 generation, thereby improving the PDT efficiency.

[0082] Example 3 Bionic Nanomedicine RBC-O 2 / Testing of the bactericidal and therapeutic effects of TQ@PB (1) Bionic nanomedicine RBC-O 2 / Verification of the bactericidal effect of TQ@PB on BCG The effects of different nanomedicines on the proliferation of Mycobacterium BCG were evaluated by standard colony plate counts.

[0083] like Fig. 20 As shown, laser alone or RBC-O alone 2 / TQ@PB did not inhibit the growth and proliferation of BCG. After laser irradiation, PB (PTT alone), RBC-TQ@PB (PTT+PDT) and RBC- 2 / TQ@PB (PTT+oxygen-enhanced-PDT) has an increasing inhibitory effect on the number of mycobacterial colonies. 2 / TQ@PB not only exerts the photothermal effect of PB and the AIE photosensitizer PEG 250 -TQ's oxygen supply enhanced the photodynamic effect, and the modification of erythrocyte membranes did not affect the in vitro bactericidal effect.

[0084] (2) Bionic nanomedicine RBC-O 2 Pharmacokinetics of / TQ@PB like Fig.21 As shown, pharmacokinetic experiments confirmed that cell membrane modified RBC-O 2 / TQ@PB nanomedicine content in blood is higher than O 2 / TQ@PB. RBC-O 2 The low clearance rate of TQ@PB in vivo is attributed to the immune evasion proteins (such as CD47) in the red blood cell membrane, which prolongs its circulation. The prolonged blood circulation contributes to the RBC-O 2 / TQ@PB nanodrugs selectively and long-term accumulate in tuberculosis granuloma sites, thereby improving the therapeutic effect of tuberculosis.

[0085] (3) Bionic nanomedicine RBC-O 2 Distribution of TQ@PB in the main organs of tuberculosis mice Monitoring RBC-O using small animal imaging systems 2 / Biodistribution of TQ@PB.

[0086] like Fig. 22 As shown, O 2 / TQ@PB and RBC-O 2 / TQ@PB nanoparticles are mainly distributed in the liver, kidneys and lungs. 2 Compared with TQ@PB, RBC-O 2 / TQ@PB reduced endocytosis in the reticuloendothelial system (e.g., liver) and increased retention and targeting of lung granulomas, which may aid in in vivo tuberculosis treatment.

[0087] (4) Bionic nanomedicine RBC-O 2 / TQ@PB therapeutic evaluation on tuberculosis mice H&E staining results showed that RBC-O 2 / Therapeutic evaluation of TQ@PB in mice with pulmonary tuberculosis.

[0088] like Fig.23 As shown, the lung H&E staining results of the lungs of tuberculosis mice after treatment showed that RBC-O 2 In the TQ@PB plus light group, symptoms of Mycobacterium tuberculosis infection, such as alveolar wall thickening, fibrosis, and hemorrhage, were significantly alleviated. Effective granuloma growth inhibition and BCG clearance were attributed to the combined photothermal and oxygen-enhanced photodynamic therapy.

[0089] (5) Bionic nanomedicine RBC-O 2 / TQ@PB blood compatibility test Good blood compatibility is an important prerequisite for clinical application. 2 The hemolytic activity of the / TQ@PB nanomedicine was evaluated.

[0090] like Fig.24 As shown, when RBC-O 2 / TQ@PB nanodrug concentration up to 500 μg mL -1 , its hemolysis rate is still less than 5%, with negligible hemolysis, which is conducive to the development of bionic nanomedicine RBC-O 2 / TQ@PB further biomedical applications.

[0091] The above-described embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by those skilled in the art based on the present invention are within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.

Claims

1. A bionic nanoparticle for combined photothermal and photodynamic therapy of tuberculosis, characterized in that: The bionic nanoparticles are structures in which the outer membrane covers the core, the outer membrane is the red blood cell membrane, and the core is loaded with perfluorocarbon compounds, oxygen and AIE type photosensitizer PEG. 250 -TQ Prussian blue nanoparticles; the AIE type photosensitizer PEG 250 The structural formula of -TQ is as follows: 。 2. The biomimetic nanoparticle according to claim 1, characterized in that: The perfluorocarbon compound is perfluorotributylamine.

3. The method for preparing the biomimetic nanoparticles according to claim 1 or 2, characterized in that: The following steps are involved: S1. Preparation of PFC@PB: PFC@PB was prepared by injecting perfluorocarbon compound PFC into the mesoporous cavity of Prussian blue PB nanoparticles; S2. Preparation of O2@PB: PFC@PB is oxygenated to prepare O2@PB; S3. Preparation of O2 / TQ@PB: AIE photosensitizer PEG 250 -TQ is loaded into O2@PB to prepare O2 / TQ@PB; S4. Preparation of RBC-O2 / TQ@PB: The red blood cell membrane was mixed with the O2 / TQ@PB solution and co-extruded to prepare RBC-O2 / TQ@PB biomimetic nanoparticles.

4. The method for preparing biomimetic nanoparticles according to claim 3, characterized in that: The preparation method of the Prussian blue PB nanoparticles described in step S1 is to mix K3[Fe(CN)6], PVP and HCl in deionized water, perform ultrasonic treatment, and centrifuge to obtain the obtained nanoparticles.

5. The method for preparing biomimetic nanoparticles according to claim 3, characterized in that: The mass volume ratio of the Prussian blue PB nanoparticles to the perfluorocarbon compound PFC in step S1 is 1 mg: 5~20 μL.

6. The method for preparing biomimetic nanoparticles according to claim 3, characterized in that: The oxygenation condition in step S2 is an oxygenation flow rate of 2 to 8 L min -1 , oxygenation time is 5 to 15 minutes.

7. The method for preparing biomimetic nanoparticles according to claim 3, characterized in that: The AIE type photosensitizer PEG in step S3 250 The mass ratio of -TQ to O2@PB is 1:1~3.

8. Use of the bionic nanoparticles according to claim 1 or 2 in the preparation of a pharmaceutical preparation for the treatment of tuberculosis.

9. A pharmaceutical preparation for the treatment of tuberculosis, characterized in that: Containing the biomimetic nanoparticles according to claim 1 or 2.

10. The pharmaceutical preparation according to claim 9, characterized in that: Pharmaceutically acceptable excipients are also included.